Files and links (1)
Published (Version of Record)CC BY-NC V4.0, Open Access
Conference proceeding
Real-world Australian experience with Ofatumumab in the MSBase registry
BMJ neurology open, Vol.6(Suppl 1), pp.A45-A46
ANZAN Annual Scientific Meeting 2024 (Adelaide, SA, Australia, 21/05/2024–24/05/2024)
2024
Abstract
Objectives
To characterize the use of ofatumumab (OFA), a fully human self-administered anti-CD20 monoclonal antibody, in a real-world setting in Australia by assessing the profile of relapsing multiple sclerosis (RMS) patients initiating OFA through an evaluation of patient demographics, background MS disease characteristics and prior therapy history as recorded in MSBase.
Methods
This is a retrospective secondary use of MSBase Registry data study, describing the baseline characteristics of RMS patients in Australia initiated on OFA treatment, including demographics, disease duration, expanded disability status scale (EDSS), treatment history with disease-modifying therapies (DMTs) prior to commencing OFA and proportion of naïve patients initiating ofatumumab relative to patients having received a prior DMT.
Results
As of 1st January 2024, MSBase has included 320 eligible patients initiated on OFA, with 22.2% treatment naïve, 30.9% switching from ocrelizumab, 14.7% switching from natalizumab, 3.1% from alemtuzumab and 27.7% from oral DMTs. The reasons for switching DMT to OFA included scheduled stop (13.1%), evidence of disease activity (9.1%), convenience (6.9%), side effects/intolerance (6.2%), JCV antibody positive (2.8%), pregnancy planned/confirmed (2.5%) and not reported (37.2%). The median age of patients initiating OFA was 42.67 [36.65, 51.98] years, with a median disease duration of 9.19 [3.61, 17.11] years and median EDSS of 2 [1.5, 3.5].
Conclusion
The real-world data from this secondary use of data MSBase registry analysis provides a valuable snapshot of the Australian experience of relapsing MS patients initiated on OFA, with 22% of patients treated as first line therapy.
Details
- Title
- Real-world Australian experience with Ofatumumab in the MSBase registry
- Authors/Creators
- Nevin John - National Hospital for Neurology and NeurosurgeryTomas Kalincik - The University of MelbourneJeannette Lechner-Scott - Hunter Medical Research InstituteMark Slee - 9Liverpool Hospital, Sydney, NSW, AustraliaSuzanne Hodgkinson - 9Liverpool Hospital, Liverpool, NSW, AustraliaTim Spelman - Peter MacCallum Cancer CentreHelmut Butzkueven - Alfred HealthMichael Barnett - 1Royal Prince Alfred Hospital, Camperdown, NSW, AustraliaAllan Kermode - 3Western Australian Neuroscience Research Institute, The University of Western Australia, Nedlands, WA, AustraliaRichard Macdonell - Austin HealthAnneke Van Der Walt - Monash UniversityPamela McCombe - 18Royal Brisbane and Women’s Hospital, Herston, QLD, AustraliaMarzena Fabis-Pedrini - 3The Perron Institute for Neurological and Translational Science, The University of Western Australia, QEII Medical Centre, Nedlands, WA, AustraliaWilliam M Carroll - 1Centre for Neuromuscular and Neurological Disorders, Western Australian Neuroscience Research Institute, The University of Western Australia, Sir Charles Gairdner Hospital, QEII Medical Centre, Nedlands, AustraliaMargaret Migocki - 1Novartis Pharmaceuticals Australia, Macquarie Park, NSW, AustraliaBirte Schmitt - 1Novartis Pharmaceuticals Australia, Macquarie Park, NSW, Australia
- Publication Details
- BMJ neurology open, Vol.6(Suppl 1), pp.A45-A46
- Conference
- ANZAN Annual Scientific Meeting 2024 (Adelaide, SA, Australia, 21/05/2024–24/05/2024)
- Publisher
- BMJ Publishing Group Ltd., Australian and New Zealand Association of Neurologists (ANZAN); Adelaide, SA, Australia
- Identifiers
- 991005695148807891
- Copyright
- © 2024 BMJ Publishing Group Ltd & Australian and New Zealand Association of Neurologists.
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Conference proceeding
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Metrics
42 File views/ downloads
68 Record Views